Marta Santisteban

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells

Marta Santisteban, Jennifer M. Reiman, Michael K. Asiedu et al. · Cancer Research · 2009 · 378 citations · Full text

Breast Oncology, Adult Stem Cell, Immunology +18

Dendritic Cells in Cancer Immunology and Immunotherapy

Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren et al. · Cancers · 2024 · 99 citations · Full text

Immunology, Immunoediting, Immunotherapeutics +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 83 citations · Full text

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

Marta Santisteban, Carol Reynolds, Emily G. Barr Fritcher et al. · Breast Cancer Research and Treatment · 2009 · 71 citations · Full text

Tumor Biology, Prognostic Biomarkers, Breast Oncology +12